A systematic review of the effectiveness of policies restricting access to pregabalin

• Main Authors: Brett R. Stacey (Author), Jonathan Liss (Author), Regina Behar (Author), Alesia Sadosky (Author), Bruce Parsons (Author), Elizabeth T. Masters (Author), Patrick Hlavacek (Author)
• Format: Book
• Published: BMC, 2017-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Formularies often employ restriction policies to reduce pharmacy costs. Pregabalin, an alpha-2-delta ligand, is approved for treatment of fibromyalgia (FM); neuropathic pain (NeP) due to postherpetic neuralgia (PHN), diabetic peripheral neuropathy (pDPN), spinal cord injury; and...